Adding bio-ADM to staging systems for cardiac immunoglobulin light chain amyloidosis yielded no significant changes.<h4>Conclusions</h4>Bio-ADM is a promising prognostic biomarker, especially in cardiac transthyretin amyloidosis, where it improved risk stratification when added to established staging systems. This evidence concerns the gene TTR and amyloidosis.